Tirabrutinib

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Epidemiology

1 evidence topic · 1 source

Prevalence of Primary central nervous system lymphoma

No evidence found.